Is VKTX undervalued or overvalued?
As of 2025-03-16, the Intrinsic Value of Viking Therapeutics Inc (VKTX) is -4.90 USD. This VKTX valuation is based on the model Peter Lynch Fair Value. With the current market price of 30.89 USD, the upside of Viking Therapeutics Inc is -115.86%. This means that VKTX is overvalued by 115.86%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -4.90 - -4.90 | -4.90 | -115.86% |
| P/E | (14.44) - (22.57) | (15.63) | -150.6% |
| DDM - Stable | (6.40) - (15.96) | (11.18) | -136.2% |
| DDM - Multi | (0.10) - (0.18) | (0.12) | -100.4% |
| Market Cap (mil) | 3,467.40 |
| Beta | 1.91 |
| Outstanding shares (mil) | 112.25 |
| Enterprise Value (mil) | 3,440.73 |
| Market risk premium | 4.60% |
| Cost of Equity | 12.12% |
| Cost of Debt | 5.00% |
| WACC | 7.89% |